Investor Outreach: Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Altimmune between August 10, 2023, and June 25, 2025, to contact partner Josh Wilson to discuss their legal options.
Class Action Details: A federal securities class action has been filed against Altimmune, with a deadline of October 6, 2025, for investors to seek the role of lead plaintiff, following a significant drop in the company's stock price after disappointing trial results.
ALT
$5.03+Infinity%1D
Analyst Views on ALT
Wall Street analysts forecast ALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALT is 13.00 USD with a low forecast of 12.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALT is 13.00 USD with a low forecast of 12.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 5.280
Low
12.00
Averages
13.00
High
14.00
Current: 5.280
Low
12.00
Averages
13.00
High
14.00
Citizens JMP
Jonathan Wolleben
Outperform
to
Outperform
downgrade
$15 -> $14
2025-11-07
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$15 -> $14
2025-11-07
downgrade
Outperform
to
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on Altimmune to $14 from $15 and keeps an Outperform rating on the shares. The firm says it looks forward to the oral late-breaking presentation of pemvidutide's Phase 2b data at the Liver Meeting with 48-week data on track for this quarter.
UBS
Buy
downgrade
$26 -> $24
2025-08-13
Reason
UBS
Price Target
$26 -> $24
2025-08-13
downgrade
Buy
Reason
UBS lowered the firm's price target on Altimmune to $24 from $26 and keeps a Buy rating on the shares. Despite the IMPACT Phase 2b trial setback, UBS still sees a sizeable opportunity for pemvidutide in nonalcoholic steatohepatitis, the analyst tells investors in a research note.
Goldman Sachs
initiated
$1
2025-07-10
Reason
Goldman Sachs
Price Target
$1
2025-07-10
initiated
Reason
Goldman Sachs resumed coverage of Altimmune with a Sell rating and $1 price target, representing 79% downside. The company's data to-date has not demonstrated a meaningfully differentiated profile for pemvidutide in either obesity or metabolic dysfunction associated steatohepatitis, the analyst tells investors in a research note. The firm sees challenges for Altimmune to execute the full clinical development program required to bring pemvidutide to market.
Citizens JMP
Outperform
to
NULL
downgrade
$25 -> $15
2025-07-10
Reason
Citizens JMP
Price Target
$25 -> $15
2025-07-10
downgrade
Outperform
to
NULL
Reason
Citizens JMP lowered the firm's price target on Altimmune to $15 from $25 and keeps an Outperform rating on the shares. Pemvidutide is still a competitive MASH candidate, but its path forward has become more difficult, the analyst tells investors in a research note. The firm thinks pemvidutide will hit both fibrosis and MASH resolution in Phase 3, but says Altimmune needs additional capital to get through the pivotal MASH program, which will now be the overhang on the stock.
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
